Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. Johnston PB, et al. Among authors: witzig te. Am J Hematol. 2010 May;85(5):320-4. doi: 10.1002/ajh.21664. Am J Hematol. 2010. PMID: 20229590 Free PMC article. Clinical Trial.
Primary renal non-Hodgkin's lymphoma. An unusual extranodal site.
Okuno SH, Hoyer JD, Ristow K, Witzig TE. Okuno SH, et al. Among authors: witzig te. Cancer. 1995 May 1;75(9):2258-61. doi: 10.1002/1097-0142(19950501)75:9<2258::aid-cncr2820750911>3.0.co;2-s. Cancer. 1995. PMID: 7712433 Review.
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.
Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, Levitt R, Suman VJ, Witzig TE, Wieand HS, Miller LL, Moertel CG. Hartmann LC, et al. Among authors: witzig te. N Engl J Med. 1997 Jun 19;336(25):1776-80. doi: 10.1056/NEJM199706193362502. N Engl J Med. 1997. PMID: 9187067 Free article. Clinical Trial.
645 results